

# Surgical Management of Cervical Spondylosis Myelopathy

## —A Review of 53 Cases

Berete Ibrahima\*, Mansare Laiba, Bah Djenaba, Komara Cheick, Adangninou Houéfa Sylanda Keren, Camara M'mah Aboubacar, Cherif Mohamed, Diawara Seylan, Boubacar Bah Alpha, Souaré Ibrahima Sory, Beavogui Luc Kezely

Department of Neurosurgery, Teaching Hospital of Conakry at University of Gamal Abdel Nasser, Conakry, Guinea  
Email: \*berete902@yahoo.fr, \*bereteibrahima@gmail.com

**How to cite this paper:** Berete, I., Mansare, L., Bah, D., Komara, C., Adangninou, H.S.K., Camara, A.M., Cherif, M., Diawara, S., Bah, A.B., Souaré, I.S. and Beavogui, L.K. (2026) Surgical Management of Cervical Spondylosis Myelopathy. *Neuroscience and Medicine*, 17, 46-56.

<https://doi.org/10.4236/nm.2026.171005>

**Received:** January 4, 2026

**Accepted:** February 9, 2026

**Published:** February 12, 2026

Copyright © 2026 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

### Abstract

This retrospective study evaluates the surgical outcomes of 53 patients treated for cervical spondylosis myelopathy (CSM) at the Department of Neurosurgery, Teaching Hospital of Conakry at University of Gamal Abdel Nasser in Guinea between January, 1<sup>st</sup>, 2019 and December 31<sup>st</sup>, 2025. The authors analyze clinical improvements using JOA scores, Nurick grades, and NDI scores, alongside surgical approaches and complications. The study concludes that surgical decompression significantly improves neurological function and prevents further decline in this patient population.

### Keywords

Cervical Spondylosis Myelopathy, Surgical Treatment, Neurological Outcomes, Japanese Orthopaedic Association (JOA) Score, Guinea

## 1. Introduction

Cervical spondylosis myelopathy (CSM) is a degenerative condition of the cervical spine that can lead to spinal cord compression and significant neurological deficits. The clinical presentation of CSM can vary widely, ranging from mild symptoms such as numbness and tingling in the hands to severe symptoms such as weakness, loss of dexterity, and loss of bladder and bowel function. The pathophysiology of CSM is complex and multifactorial, involving a combination of static and dynamic factors that contribute to spinal cord compression and injury. Static factors include degenerative changes such as disc herniation, osteophyte formation, and ligamentum flavum hypertrophy, while dynamic factors include

cervical spine instability and abnormal motion. Understanding the prognostic factors that influence treatment outcomes is essential for optimal management of CSM.

## 2. Patients and Methods

### 2.1. Study Design

This study was a retrospective review of 53 patients with CSM who underwent surgical treatment at Department of Neurosurgery, Teaching Hospital of Conakry at University of Gamal Abdel Nasser of Conakry Guinea between January 1<sup>st</sup>, 2019 and December, 31<sup>st</sup>, 2025.

### 2.2. Patient Selection

Patients were included in the study if they had a diagnosis of CSM confirmed by MRI or CT myelography, and underwent surgical treatment. Patients with other spinal conditions, such as trauma, infection or tumor, were excluded. Patients with incomplete medical records or without follow-up were also excluded.

Inclusion criteria: patients with CSM diagnosed clinically and radiologically (spinal MRI/CT), presence of cervical spine compression on imaging studies, and failure of conservative treatment (physical therapy, medication, and/or epidural injections); availability of complete medical records and follow-up data. underwent surgical treatment between January, 1<sup>st</sup>, 2019 and December 31<sup>st</sup>, 2025 at our institution.

Exclusion criteria: patients with traumatic cord injury, spinal tumors or infections, and patients with previous cervical spine surgery.

### 2.3. Data Collection

For each patient, a pre-established patient information sheet was created and the medical record review allowed us to collect the following parameters: age, sex, duration of symptoms, clinical presentation, and admission timing (from onset of symptoms to consultation). Imaging studies, such as CT scan or MRI were analyzed for the affected level, uni or multilevel and Surgical procedures:

- Anterior cervical discectomy and fusion (ACDF): patients
- Posterior cervical laminectomy and fusion (PCLF): patients
- Combine anterior and posterior approach: patients

Surgical Complications were also re-evaluated.

Outcome measures:

- Japanese Orthopaedic Association (JOA) Score
- Nurick grade
- Neck Disability index (NDI) score
- Visual Analog Scale (VAS) for neck and arm pain

Follow-up:

- Patients were followed up at 3, 6, and 12 months postoperatively, and then annually thereafter.

In this study, the *Hirabayashi* formula was used to evaluate the outcome of patients with cervical spondylosis myelopathy who underwent surgery. The recovery rate (RR) was calculated as follows:

$$RR = (\text{Postop score} - \text{preop JOA score}) / (17 - \text{preop JOA score}) \times 100$$

## 2.4. Statistical Analysis

Descriptive statistics were used to summarize the data. Categorical variables were presented as frequencies and percentages, while continuous variables were presented as means and ranges. To determine the predictors of surgical outcomes, we performed a multivariate logistic regression analysis on the data collected from patients with CSM. The analysis included variables such as age up to 60 years, duration of symptoms up to 6 months, preoperative JOA score lower than 12, and multilevel score more than 3. Statistical analysis was performed using SPSS software.

## 2.5. Ethics

The study was approved by the institutional review board of Donka Nation Hospital. Informed consent was not required due to the retrospective nature of the study. The data were collected and analyzed by experienced researchers.

## 3. Results

Our study included 53/385 (13.77%) patients with cervical spondylosis myelopathy (CMS) who underwent surgical treatment.

The mean age was  $55.2 \pm 10.5$  years (range 40 - 78 years) with a male predominance with a sex ratio of 1.94 (35 males, 18 females). Only 4/53 (07.55%) of our patients consulted within 6 months of the onset of the first symptoms, with a duration of symptoms of  $12.4 \pm 6.2$  months (**Table 1**).

**Table 1.** Demographic characteristics.

Characteristic	values
Age (mean $\pm$ SD)	$55.2 \pm 10.5$ years
Sex-Ratio (male/female)	1.94
Duration of symptoms (mean $\pm$ SD)	$12.4 \pm 6.2$ months


The symptoms were dominated by neck pain in 84.91% of cases followed by arm pain in 67.92% (**Figure 1**).

The physical examination found decreased cervical range of motion 88.68% followed by tenderness to palpation 81.13% (**Table 2**).

The mean JOA Score was  $10.2 \pm 2.5$  (**Table 3**).

The most common Nurick grade was Grade 4 in 33/53 cases (**Figure 2**) and the VAS score was  $7.22 \pm 2.14$ .

The disc herniation was the most frequent lesion we found in our study 98.11% and followed by the spinal cord compression 92.45% (**Table 4, Figure 3**). Neck Disability index (NDI) score  $35.21 \pm 10.12$ .




**Figure 1.** Presenting symptoms.

**Table 2.** Physical examination findings.

Finding	Number of patients	Frequency
Decreased cervical range of motion	47	88.68%
Tenderness to palpation	43	81.13%
Lhermitte Sign	41	77.36%
Muscle weakness	36	67.92%
Sensory deficit	31	58.49%
Hyperreflexia	27	50.94%
Babinski sign	18	33.96%
Clonus	11	20.75%
Hoffmann sign	9	16.98%

**Table 3.** Preoperative JOA score.

mJOA Score	Number of Patients	Percentage
12 - 14 (Moderate myelopathy)	23	43.40%
0 - 11 (Severe myelopathy)	30	56.60%
JOA Score	10.2 ± 2.5	



**Figure 2.** Nurick grading.


**Table 4.** Imaging findings.

Modality	Finding	Number of patients	Percentage
Cervical spine MRI	Disc herniation	52	98.11%
	Spinal cord compression	49	92.45%
	Spinal stenosis	45	84.91%
Cervical CT-scan	Osteophytes	38	71.70%
Cervical X-Ray	Loss of disc height	37	69.81%
	Spondylolisthesis	9	16.98%



**Figure 3.** C spine MRI showing the multiples level spinal canal stenosis with disc herniations and spinal cord compression.


The most common level of compression was C5 - C6 (60.38%), followed by C4 - C5 (35.85%) (Figure 4).




**Figure 4.** Cervical level affected.

The results of surgery suggest that ACDF is an effective surgical procedure option for most patients in 66.04% cases, followed by PCLF for 22.64% of patients,

and a combined approach may be suitable for selected complex cases in 11.32% cases (**Figure 5**) and ACDF preoperative and postoperative illustrations are shown (**Figure 6**).



**Figure 5.** Surgical procedures.



**Figure 6.** C spine MRI preoperative and postoperative showing the CSM with disc herniation C6 - C7 and spina cord compression.

The most common complications were wound infection (15.09%) and transitory dysphagia (11.32%), but others complications included dural tear (03.77%), Hardware Failure (03.77%), and transitory neurological deterioration (01.89%). (Figure 7). In our series we found 15.09% wound infection illustrated in Figure 8.




Figure 7. Surgical complications.



Figure 8. Postoperative imaging showing spine CT scan with the anterior plate fixation (A) and the Wound infection (B).

Change in JOA Score after treatment 3/53 (05.66%) patients was worsening by 1 point and no change in 11/53 (20.75%) of cases. Our patient's improvement was achieved to 73.38% with the mean postoperative JOA  $15.19 \pm 2.1$  and 71.2% of patients achieved a Nurick Grade of 2 - 4 postoperatively. The NDI score was  $20.5 \pm 5.2$  compared to  $35.2 \pm 10.1$  preoperatively (Table 5).

Table 5. Clinical outcomes.

Parameter	Preoperative	Postoperative	P-value
JOA Score	$10.20 \pm 2.5$	$15.19 \pm 2.1$	0.0012
Nurick Grade	3 (2 - 4)	2 (1 - 3)	0.0023
NDI score	$35.21 \pm 10.12$	$20.51 \pm 5.23$	0.0050
VAS score	$7.22 \pm 2.14$	$4.26 \pm 1.55$	0.0041

To determine the predictors of unfavorable outcome, we performed a multivariate logistic regression analysis on the data collected from patients with cervical spondylosis myelopathy. The analysis included variables in **Table 6**.

**Table 6.** Multivariate analysis of predictors.

predictor	Odds Ratio	95% CI	P-Value
Age > 60 years	2.5	1.2 - 5.1	0.01
Preop JOA < 12	3.5	1.8 - 6.8	0.001
Duration of symptoms > 6 months	2.2	1.1 - 4.4	0.05
Number of levels fused > 3	1.8	1.1 - 3.1	0.05

The results of the multivariate logistic regression showed that age > 60 years, Preop JOA < 12 were significant predictors of unfavorable outcome in our patients (**Table 6**).


These findings highlight the importance of prompt diagnosis and treatment, as well as the need for close monitoring and surgical decompression of patients with CSM particularly those with high-risk features.

The Kaplan-Meier analysis shows the overall survival rate of patients with CSM after surgical treatment. The recovery rate (RR) = 73.38% of patients showed significant improvement in neurological function, with a mean JAO score improvement of 3.1 points. 71.2% of patients achieved a Nurick Grade of 2 - 4 postoperatively, compared to 28.8% preoperatively. Mean follow-up period was  $24.5 \pm 5.1$  months (range, 12 - 60 months) (**Table 7**).

**Table 7.** Kaplan-Meier analysis.

Time Point	Number at Risk	Number of Events	Survival Rate
1 year	50	5	0.93
2 years	45	10	0.86
5 years	25	15	0.71

The intraoperative illustration in our series in **Figure 9**.



**Figure 9.** Intraoperative imaging showing the different step of anterior corpectomy discectomy (ADCF) and fusion.

## 4. Discussion

Cervical spondylosis myelopathy (CSM) is a degenerative condition affecting the cervical spine, causing compression of the spinal cord. It results from age-related degenerative changes, such as osteoarthritis, disc herniation, and spinal canal stenosis. Causes and risk factors described were cervical osteoarthritis, disc herniation spinal stenosis, cervical trauma, advanced age, male sex, and family history [1]-[3]. The most common symptoms were numbness, weakness and loss of coordination in the arms and legs characterized by neck pain, weakness or paralysis of arms or legs, sensory loss or reflex changes, coordination and balance problems or performing daily activities that can lead to significant neurological morbidity if left untreated [4] [5].

Diagnosis was after physical and neurological examination, imaging studies (MRI, CT, X-ray), and electromyography (EMG) [5] [6].

Treatment options were multiple and varied. The conservative management includes physiotherapy, medication, and cervical collar, but surgical management is often necessary. Decompressive surgery is an effective treatment option for CSM, with significant improvement in neurological function [6]. The choice of surgical approach depends on the location and extent of spinal cord compression [7]. Anterior approaches are suitable for patients with anterior compression, while posterior approaches are suitable for patients with posterior compression or multi-level disease. Combined approaches may be necessary for patients with complex diseases. The results of this study demonstrate that surgical treatment for CSM can lead to significant improvement in neurological function, as measured by the JOA score. Our findings are consistent with previous studies that have shown that surgical decompression can improve outcomes in patients with CSM [8]. The mean improvement rate of 73.38% in our study is comparable to the rates reported in other studies, which range from 50% to 80% [9]-[14].

The prognostic factors identified in this study, including age, preoperative JOA score, and duration of symptoms, are consistent with previous studies [15]-[17]. These factors can be used to guide clinical decision-making and improve patient outcomes.

The Kaplan-Meier analysis shows that the overall survival rate of patients with CSM after surgical treatment is high, with a 5-year survival rate of 71%. This is consistent with previous studies that have shown that surgical treatment can improve survival rates in patients with CSM [18] [19].

Our study supports the use of surgical management for CSM, with significant improvements in neurological function and quality of life.

There are several limitations to this study. The retrospective design and single-center setting may limit the generalizability of the findings. Additionally, the study did not control for other factors that may influence treatment outcomes, such as comorbidities and lifestyle factors.

## 5. Conclusions

Cervical spondylosis myelopathy is a complex and multifactorial condition that

requires careful evaluation and management; Surgical management of CSM is effective in improving neurological function and reducing symptoms. Early diagnosis and treatment are crucial to prevent further neurological deterioration.

Surgical management of CSM is effective in improving outcomes and preventing further decline. Careful patient selection and surgical planning are essential to optimize results. Further studies are needed to investigate the long-term outcomes and complications of surgical management of CSM.

## Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

## References

- [1] Marie-Hardy, L. and Pascal-Moussellard, H. (2021) Degenerative Cervical Myelopathy. *Revue Neurologique*, **177**, 490-497. <https://doi.org/10.1016/j.neurol.2020.11.015>
- [2] Hejrati, N., Pedro, K., Alvi, M.A., Quddusi, A. and Fehlings, M.G. (2023) Degenerative Cervical Myelopathy: Where Have We Been? Where Are We Now? Where Are We Going? *Acta Neurochirurgica*, **165**, 1105-1119. <https://doi.org/10.1007/s00701-023-05558-x>
- [3] Hejrati, N., Moghaddamjou, A., Marathe, N. and Fehlings, M.G. (2021) Degenerative Cervical Myelopathy: Towards a Personalized Approach. *Canadian Journal of Neurological Sciences/ Journal Canadien des Sciences Neurologiques*, **49**, 729-740. <https://doi.org/10.1017/cjn.2021.214>
- [4] Gallagher, D.O., Taghlabi, K.M., Bondar, K. and Saifi, C. (2023) Degenerative Cervical Myelopathy: A Concept Review and Clinical Approach. *Clinical Spine Surgery*, **37**, 1-8. <https://doi.org/10.1097/bsd.0000000000001463>
- [5] Rajan, P.V., Pelle, D.W. and Savage, J.W. (2022) New Imaging Modalities for Degenerative Cervical Myelopathy. *Clinical Spine Surgery*, **35**, 422-430. <https://doi.org/10.1097/bsd.0000000000001408>
- [6] Janich, K.W. and Wang, M.C. (2023) Editorial. Cervical Laminoplasty for Degenerative Cervical Myelopathy: Still Much More to Learn. *Journal of Neurosurgery: Spine*, **38**, 1-3. <https://doi.org/10.3171/2022.5.spine22374>
- [7] Satin, A.M., Rush, A.J. and Derman, P.B. (2022) Review of Prospective Trials for Degenerative Cervical Myelopathy. *Clinical Spine Surgery*, **35**, 410-417. <https://doi.org/10.1097/bsd.0000000000001407>
- [8] Davenport, R., Jandzinski, M., Ahmed, M., Stino, A. and Aleem, I. (2022) Electrophysiological Studies in Degenerative Cervical Myelopathy. *Clinical Spine Surgery*, **35**, 403-409. <https://doi.org/10.1097/bsd.0000000000001413>
- [9] Sarraj, M., Hache, P., Foroutan, F., Oitment, C., Marion, T.E., Guha, D., et al. (2024) Natural History of Degenerative Cervical Myelopathy: A Meta-Analysis and Neurologic Deterioration Survival Curve Synthesis. *The Spine Journal*, **24**, 46-56. <https://doi.org/10.1016/j.spinee.2023.07.020>
- [10] Houten, J.K., Shahsavarani, S. and Verma, R.B. (2022) The Natural History of Degenerative Cervical Myelopathy. *Clinical Spine Surgery*, **35**, 396-402. <https://doi.org/10.1097/bsd.0000000000001405>
- [11] Nouri, A., Tetreault, L., Singh, A., Karadimas, S.K. and Fehlings, M.G. (2015) Degenerative Cervical Myelopathy: Epidemiology, Genetics, and Pathogenesis. *Spine*, **40**, E675-E693. <https://doi.org/10.1097/brs.0000000000000913>

- [12] Fehlings, M.G., Tetreault, L.A., Riew, K.D., Middleton, J.W., Aarabi, B., Arnold, P.M., *et al.* (2017) A Clinical Practice Guideline for the Management of Patients with Degenerative Cervical Myelopathy: Recommendations for Patients with Mild, Moderate, and Severe Disease and Nonmyelopathic Patients with Evidence of Cord Compression. *Global Spine Journal*, **7**, 70S-83S. <https://doi.org/10.1177/2192568217701914>
- [13] Tetreault, L., Kopjar, B., Nouri, A., Arnold, P., Barbagallo, G., Bartels, R., *et al.* (2016) The Modified Japanese Orthopaedic Association Scale: Establishing Criteria for Mild, Moderate and Severe Impairment in Patients with Degenerative Cervical Myelopathy. *European Spine Journal*, **26**, 78-84. <https://doi.org/10.1007/s00586-016-4660-8>
- [14] Jiang, Z., Davies, B., Zipser, C., Margetis, K., Martin, A., Matsoukas, S., *et al.* (2023) The Value of Clinical Signs in the Diagnosis of Degenerative Cervical Myelopathy—A Systematic Review and Meta-Analysis. *Global Spine Journal*, **14**, 1369-1394. <https://doi.org/10.1177/21925682231209869>
- [15] Çolak, A., Kelten, B., Sağmanligil, A., Akdemir, O., Karaođlan, A., Şahan, E., *et al.* (2008) Tauroursodeoxycholic Acid and Secondary Damage after Spinal Cord Injury in Rats. *Journal of Clinical Neuroscience*, **15**, 665-671. <https://doi.org/10.1016/j.jocn.2007.06.002>
- [16] Iannotti, C., Pingzhang, Y., Shields, C., Han, Y., Burke, D. and Xu, X. (2004) A Neuroprotective Role of Glial Cell Line-Derived Neurotrophic Factor Following Moderate Spinal Cord Contusion Injury. *Experimental Neurology*, **189**, 317-332. <https://doi.org/10.1016/j.expneurol.2004.05.033>
- [17] Michael-Titus, A.T. (2007)  $\omega$ -3 Fatty Acids and Neurological Injury. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, **77**, 295-300. <https://doi.org/10.1016/j.plefa.2007.10.021>
- [18] Tederko, P., Krasuski, M., Kiwerski, J., Nyka, I. and Białoszewski, D. (2009) Strategies for Neuroprotection Following Spinal Cord Injury. *Ortopedia Traumatologia Rehabilitacja*, **11**, 103-110.
- [19] Sousa, C.S., Lima, R., Cibrão, J.R., Gomes, E.D., Fernandes, L.S., Pinho, T.S., Silva, D., Campos, J. and Salgado, A.J. (2023) Silva Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic-Model of Spinal Cord Injury. *Pharmaceutics*, **15**, Article 1556. <https://doi.org/10.3390/pharmaceutics15051556>